Longhurst, HJ; Stobiecki, M; Zanichelli, A; Huissoon, A; Moldovan, D; Maurer, M; Magerl, M; Cancian, M; Senter, R; Manson, A; Aygoren-Pursun, E; Grivcheva-Panovska, V; Hagin, D; Steiner, U; Kiani-Alikhan, S; Agmon-Levin, N; Bygum, A; Aberer, W; Faust, SN; Launay, D; Gompels, M; Triggiani, M; Bethune, C; Reshef, A; Cornpropst, M; Dobo, S; Van Dyke, S; Murray, S; Collis, P; Sheridan, WP; Farkas, H; Cicardi, M.
Final results from the ZENITH-1 study: Oral administration of plasma kallikrein inhibitor BCX7353 for the treatment of attacks in patients with hereditary angioedema
ALLERGY. 2019; 74: 10-11.-Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI); JUN 01-05, 2019; Lisbon, PORTUGAL.
[Poster]
Web of Science